Pelthos Therapeutics Stock Market Value
| PTHS Stock | 20.58 1.07 4.94% |
| Symbol | Pelthos |
Is there potential for Pharmaceuticals market expansion? Will Pelthos introduce new products? Factors like these will boost the valuation of Pelthos Therapeutics. Anticipated expansion of Pelthos directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Pelthos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pelthos Therapeutics is measured differently than its book value, which is the value of Pelthos that is recorded on the company's balance sheet. Investors also form their own opinion of Pelthos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pelthos Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Pelthos Therapeutics' market value can be influenced by many factors that don't directly affect Pelthos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pelthos Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pelthos Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pelthos Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Pelthos Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pelthos Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pelthos Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Pelthos Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Pelthos Therapeutics or generate 0.0% return on investment in Pelthos Therapeutics over 90 days. Pelthos Therapeutics is related to or competes with CASI Pharmaceuticals, Lisata Therapeutics, Kairos Pharma, Lexaria Bioscience, Passage Bio, Lixte Biotechnology, and Enlivex Therapeutics. Pelthos Therapeutics is entity of United States More
Pelthos Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pelthos Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pelthos Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 25.75 | |||
| Value At Risk | (7.67) | |||
| Potential Upside | 8.39 |
Pelthos Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pelthos Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pelthos Therapeutics' standard deviation. In reality, there are many statistical measures that can use Pelthos Therapeutics historical prices to predict the future Pelthos Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.67) | |||
| Total Risk Alpha | (1.02) | |||
| Treynor Ratio | (1.06) |
Pelthos Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 3.95 | |||
| Coefficient Of Variation | (833.93) | |||
| Standard Deviation | 5.21 | |||
| Variance | 27.16 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.67) | |||
| Total Risk Alpha | (1.02) | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 25.75 | |||
| Value At Risk | (7.67) | |||
| Potential Upside | 8.39 | |||
| Skewness | 0.4948 | |||
| Kurtosis | 0.7893 |
Pelthos Therapeutics Backtested Returns
Pelthos Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.12, which implies the firm had a -0.12 % return per unit of risk over the last 3 months. Pelthos Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Pelthos Therapeutics' Risk Adjusted Performance of (0.09), coefficient of variation of (833.93), and Variance of 27.16 to confirm the risk estimate we provide. The company holds a Beta of 0.6, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pelthos Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Pelthos Therapeutics is expected to be smaller as well. At this point, Pelthos Therapeutics has a negative expected return of -0.58%. Please make sure to check Pelthos Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Pelthos Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.03 |
Virtually no predictability
Pelthos Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Pelthos Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pelthos Therapeutics price movement. The serial correlation of 0.03 indicates that only 3.0% of current Pelthos Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.03 | |
| Spearman Rank Test | 0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 4.64 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pelthos Stock Analysis
When running Pelthos Therapeutics' price analysis, check to measure Pelthos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pelthos Therapeutics is operating at the current time. Most of Pelthos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pelthos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pelthos Therapeutics' price. Additionally, you may evaluate how the addition of Pelthos Therapeutics to your portfolios can decrease your overall portfolio volatility.